



# Downregulation of *CLDN6* inhibits cell migration and invasion and promotes apoptosis by regulation of the JAK2/STAT3 signaling pathway in hepatocellular carcinoma

Zhiyi He<sup>1</sup>, Fangtian Fan<sup>2</sup>, Zhidong Xu<sup>1</sup>, Mei Zhang<sup>1</sup>, Rui Zhao<sup>1</sup>, Xiquan Ke<sup>1</sup>, Qizhi Wang<sup>1</sup>, Shanjun Yan<sup>1</sup>, Hailun Zheng<sup>1</sup>

<sup>1</sup>Department of Gastroenterology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China; <sup>2</sup>Faculty of Pharmacy, Bengbu Medical College, Bengbu, China

**Contributions:** (I) Conception and design: Z He; (II) Administrative support: H Zheng; (III) Provision of study materials or patients: H Zheng; (IV) Collection and assembly of data: Z He; (V) Data analysis and interpretation: Z He; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Dr. Hailun Zheng. Department of Gastroenterology, The First Affiliated Hospital of Bengbu Medical College, 287 Changhuai Road, Bengbu 233030, China. Email: alanhailun2022@163.com.

**Background:** High expression of *CLDN6* in hepatocellular carcinoma (HCC) has been widely reported. During this research, *CLDN6*'s effect on the infiltration, migration, and apoptosis of HCC cells was investigated.

**Methods:** Initially, the knockdown and overexpression of *CLDN6* in HCC cells were carried out by short interfering RNA (siRNA) and plasmid transfection. The transfection efficiency was detected by means of a quantitative real-time polymerase chain reaction (qRT-PCR) assay, immunofluorescence staining, and Western blot analysis. Transwell and wound-healing assays were employed for the detection of invasion and migration ability. CCK-8 assay and flow cytometry were utilized for the detection of apoptosis. Finally, analysis of the expression of pathway-related proteins (JAK2, STAT3, p-JAK2, and p-STAT3) and the regulation of apoptotic responses (by measurement of cleaved caspase-3, Bax, and Bcl-2 levels) was carried out.

**Results:** When *CLDN6* was knocked down, the cellular invasion and migration ability decreased, and apoptosis increased, which decreased p-JAK2, p-STAT3, and anti-apoptotic protein bcl-2 expression. Furthermore, an elevation was observed in cleaved caspase-3 and Bax expression levels. Contrarily, upon overexpression of *CLDN6*, the aforementioned experimental results were reversed.

**Conclusions:** *CLDN6* knockdown results in the inhibition of HCC cells' infiltration and migration and promotes apoptosis via downregulation of the JAK2/STAT3 signaling pathway.

**Keywords:** *CLDN6*; hepatocellular carcinoma (HCC); invasion; migration; apoptosis

Submitted Jan 05, 2023. Accepted for publication Jun 07, 2023. Published online Jul 10, 2023.

doi: 10.21037/tcr-23-19

View this article at: <https://dx.doi.org/10.21037/tcr-23-19>

## Introduction

Epithelium and endothelium separate different tissues to protect multicellular organisms from external effects. These tissues need to form tight junctions (TJs), the selective gates that control the diffusion of ions and solutes around the cells. Additionally, the apical and basal plasma membrane domains are separated by TJ, which is connected to the

mechanism that controls the apical-basal polarization (1). TJs are simple static components used to establish cell adhesion structure and are involved in mediating cellular signals. They receive environmental cues and transmit signals within a cell. CLDNs play a role in maintaining TJ adhesion between cells (2), thus constituting a selective barrier to the pericellular membrane. CLDN is a tetramer

protein ranging in size from 20 to 27 kDa. The CLDN family consists of more than 27 members. The sequence analysis of CLDNs leads to two groups according to their sequence similarity, called classical CLDNs and non-classical CLDNs (3).

In human tumors, CLDNs expression is often reduced or eliminated. These findings align with the well-established hypothesis that disruption or ineffectiveness of functional TJs is strongly associated with cancer. Instead, accumulated data show increased or abnormal expression of CLDNs in different cancers, indicating their special role in tumorigenesis. Although the CLDN family exhibits specific distribution patterns in different organs, abnormal expression of CLDNs promotes tumorigenesis. Notably, determining whether the expression of maladjusted CLDNs plays a carcinogenic role or leads to tumor inhibition depending on its target tissues and cells and whether it correlates with tumor outcomes and prognosis contributes to the study of tumor development and progression (4). CLDNs are expressed abnormally at both the transcriptional and post-transcriptional levels in cancer, although recent research has indicated that epigenetic mechanisms, such as DNA methylation, histone modification, and microRNAs (miRNAs), are essential for modulating CLDN expression.

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for 90% of liver cancers. Common risk factors for HCC are chronic inflammatory infections caused by the hepatitis B and C viruses. These infections lead to cirrhosis and make HCC the cancer

with the highest recurrence rate in the world (5). Despite considerable progress and innovation in surgical techniques, chemoradiotherapy, and targeted treatment for liver cancer in recent years, metastasis remains an important factor contributing to poor prognosis. This is why studying the underlying mechanisms of HCC onset and metastasis is essential, along with finding effective biomarkers to help with the diagnosis and targeted therapy (6).

In this research, *CLDN6*'s role in HCC was demonstrated. Furthermore, it was observed that silencing of *CLDN6* significantly promotes apoptosis and inhibits migration and invasion in SMMC-7721 and MHCC-97H cells. The mechanism may be associated with the JAK2/STAT3 signaling pathway. We present this article in accordance with the MDAR reporting checklist (available at <https://tc.amegroups.com/article/view/10.21037/tcr-23-19/rc>).

## Methods

### Cell culture

SMMC-7721 (Cat. No: CC-Y1476) and MHCC-97H (Cat. No: CC-Y1613) cell lines were supplied by Shanghai EK-Bioscience Biotechnology Co., Ltd. (China). Cell culture of every cell line was carried out at 37 °C using an incubator comprising 5% CO<sub>2</sub>. DMEM and RPMI 1640 media (HyClone, Logan, UT, USA) were added with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA) and penicillin/streptomycin (Life Technologies, Carlsbad, CA, USA).

### Transfection

For the downregulation of the *CLDN6* gene, four short interfering RNAs (siRNAs) (NC-siRNA sense strand: 5'-UUCUCCGAACGUGUCACGUTT-3' and antisense strand, 5'-AGGUGACACGUUCGGAGAATT-3'; *CLDN6*-siRNA1 sense strand 5'-CCGCCCAGAUUCAGUGCAATT-3' and antisense strand, 5'-UUGCACUGCAUCUGGCCCGTT-3'; *CLDN6*-siRNA2 sense strand 5'-GGGAUUGUCUUU GUCAUCUTT-3' and antisense strand, 5'-AGAUGACA AAGACAAUCCCTT-3'; *CLDN6*-siRNA3 sense strand 5'-CCUACCAAGAAUUCGUCUTT-3' and antisense strand, 5'-AGACGUAAUUCUUGGUAGGTT-3') were purchased from GeneChem (Shanghai, China).

In the next step, a quantitative real-time polymerase chain reaction (qRT-PCR) assay was carried out for the

### Highlight box

#### Key findings

- The downregulation of *CLDN6* is sufficient for the reduction of the invading and migrating ability of HCC cells and ultimately resulting in the death of HCC cells by inactivating the JAK2/STAT3 signaling pathway.

#### What is known and what is new?

- Studies have shown that *CLDN6* is highly expressed in liver cancer tissues. JAK and STAT proteins are overexpressed in HCC, and JAK2 and STAT3 proteins are associated with prognosis in HCC patients.
- *CLDN6* can promote apoptosis of HCC and down-regulate JAK2/STAT3 signal pathway.

#### What is the implication, and what should change now?

- This suggests that *CLDN6* may be a biomarker of HCC with potential value as a therapeutic target.

purpose of selecting the sequence that facilitated *CLDN6* knockdown for the next experiment. pcDNA-*CLDN6* and pcDNA vector (pcDNA-NC) were used for overexpression. Lipo 2000 (Invitrogen, Waltham, MA, USA) was used for cell transfection. Cell inoculation was carried out into six-well plates at a density of  $5 \times 10^5$  per well 24 h before transfection. *CLDN6*-siRNA or pcDNA-*CLDN6* plasmids were introduced into each pore cell, respectively. The liquid was replaced after six hours. The cells were gathered for future experimentation one day following transfection.

#### *qRT-PCR assay*

RNA separation from the samples was done by utilizing Trizol (Invitrogen) as per the manufacturer's guidelines, and the NanoVuebles Plus (Thermo Fisher Scientific, Waltham, MA, USA) instrument was employed for measurement of RNA quality by determining the A260/A280 ratio. Subsequently, reverse transcription of 1 g of every  $\mu$  sample was done with the help of the PrimeScripSphere Takara First Strand cDNA synthesis kit (Takara, Kusatsu, Japan), followed by storage of the resulting product at  $-80^\circ\text{C}$ . In order to perform qRT reactions, SYBR PreMix Ex Taq (Takara) and ABI StepOne PCR Real-time PCR System (Applied Biosystems, Carlsbad, CA, USA) were utilized.

The following primers employed in this research: *CLDN6*-forward: 5'-CCATCAGGGACTTCTATAA-3', *CLDN6*-reverse: CAGACGTAATTCTTGGTAGGGT; GAPDH-forward: 5'-CAGGAGGCATTGCTGATGAT-3', GAPDH-reverse: 5'-GAAGGCTGGGGCTCATTT.

#### *Immunofluorescence technique*

SMMC-7721 and MHCC-97H cells ( $4 \times 10^4$ /well) were inoculated in confocal Petri dishes overnight at  $37^\circ\text{C}$  in an incubator with 5%  $\text{CO}_2$ . After discarding the medium, pre-cooled phosphate buffered saline (PBS) was employed for cell washing after which cell fixation was done with 4% paraformaldehyde for 30 min. Then, they were closed with 3% bovine serum albumin (BSA) for an hour at room temperature. Subsequently, incubation of the dishes was done using a rabbit monoclonal antibody against *CLDN6* (Affinity Biosciences Cat# AF5213, Affinity Biosciences, Zhenjiang, China) overnight in an incubator at  $4^\circ\text{C}$  and a fluorescent secondary antibody (Affinity Biosciences Cat# S0006) for an hour at room temperature. Visualization of the cells was done using laser scanning confocal microscopy.

#### *Cell Counting Kit-8 (CCK-8) assay*

Cell proliferation was assessed by a CCK-8 cell counting kit. The human hepatoma cell line was cultured in 96-well plates at  $37^\circ\text{C}$  in an environment containing 5% carbon dioxide. When the cells reached 60% or 70% fusion, *CLDN6*-siRNA was introduced into the cells, after which they were incubated for 24, 48, or 72 h. Subsequently, 10% CCK-8 was diluted into each hole and incubated for another hour. With the aid of a microplate reader (Bio-Rad, Hercules, CA, USA), optical density (OD) measurements at 450 nm were recorded.

#### *Invasion and migration assays*

The assay chamber (Corning Life Sciences, Corning, NY, USA) was exposed to ultraviolet light for 30 min and then used in the experiment. Tumor cell invasion assay requires a pre-coated Matrigel (1:8). The upper portion of the chamber was introduced with tumor cells and serum-free media (migration:  $2 \times 10^4$  cells/well; invasion:  $5 \times 10^4$  cells/well). In the lower chamber, a conventional medium supplemented with 10% FBS was employed. Following incubation for one day at  $37^\circ\text{C}$ , the cells were fixed for 15 minutes with 4% paraformaldehyde and stained for 15 minutes with 0.5% crystal violet. A microscope was used to observe and count cells that were migrating or invading.

#### *Wound healing assay*

Measurement of cell migration was done by means of the wound healing assay. The cells ( $5 \times 10^5$ /well) were inoculated in a 6-well plate until they reached 80% fusion. Twenty-four hours after transfection, an artificial wound was constructed on the cell monolayer using the tip of a 200  $\mu\text{L}$  sterile pipette, followed by washing thrice with PBS. ImageJ was used to quantify the wound area after the wound was viewed under the inverted microscope for 0, 24, and 48 hours.

Wound healing rate =  $V_0 - V_n/V_0$ , where  $V_0$  indicates the initial wound area and  $V_n$  refers to the wound area after  $n$  hours.

#### *Apoptosis detection*

Following 24 hours of transfection, cells were collected by trypsin solution (EDTA-free) and stained with Annexin V-FITC and PI (BestBio, Shanghai, China). As per the

guidelines provided by the manufacturer, 300  $\mu$ L of 1 $\times$  Annexin V binding solution was introduced for the purpose of cell resuscitation. After adding 4  $\mu$ L of Annexin V-FITC, cell incubation was done on ice for 15 min. Subsequently, 8  $\mu$ L of PI staining solution was added and mixed gently in the absence of light, followed by incubation for 5 min on ice. Afterward, flow cytometry was employed for evaluating target cell apoptosis.

### Western blotting

The cells lysed in RIPA buffers containing protease and phosphatase inhibitors. Using a BCA kit, the proteins' concentrations were measured. SDS-PAGE was used to isolate whole cell proteins, which were then transferred to PVDF membranes (Millipore, Billerica, MA, USA). Blocking of the blots was done using 5% non-fat milk, followed by probing with the primary antibody and placement in a 4 °C refrigerator overnight. They were probed again with secondary antibodies for 2 h. For these analytical procedures,  $\beta$ -actin was utilized in the form of loading control. The primary antibodies used were as follows: rabbit anti-JAK2 (1:1,000, Affinity Biosciences Cat# AF6022), anti-STAT3 (1:1,000, Affinity Biosciences, RRID: AB\_2835144), anti-p-JAK2 (1:1,000, Affinity Biosciences Cat# AF3024), anti-p-STAT3 (1:1,000, Affinity Biosciences Cat# AF3293), anti-*CLDN6* (1:1,000, Affinity Biosciences Cat# AF5213), anti-Bcl-2 (1:1,000, Proteintech, 12789-1-AP; Proteintech, Wuhan, China), anti-cleaved caspase-3 (1:1,000, Proteintech, 66470-2-Ig), anti-Bax (1:1,000, Proteintech, 50599-2-Ig), and anti- $\beta$ -actin (1:1,000, Affinity Biosciences, RRID: AB\_2839420).

### Statistical analysis

Graphpad Prism 8.0 was employed for conducting all statistical analytical procedures. The data were compared using *t*-test, analysis of variance (ANOVA), and Tukey's honestly significant difference (HSD) test if appropriate.  $P < 0.05$  was considered as the significance threshold.

## Results

### Inhibition of invasion and migration of SMMC-7721 and MHCC-97H cells by *CLDN6* silencing

Initially, treatment of SMMC-7721 and MHCC-97H cells was done with siRNA sequences for 48 h. qRT-PCR


was employed for the detection of *CLDN6* expression. *CLDN6*-siRNA2 and *CLDN6*-siRNA1 significantly down-regulated the expression of *CLDN6* in SMMC-7721 (Figure 1A) and MHCC-97H (Figure 1B) cells, respectively. Therefore, these two sequences were used as knockdown sequences in subsequent tests. The findings of the immunofluorescence assay exhibited that following transfection with *CLDN6*-siRNA, *CLDN6* protein expression level was remarkably reduced and increased upon transfection with pcDNA-*CLDN6*m indicating high transfection efficiency in the aforementioned cells (Figure 1C,1D). Then, transwell invasion and migration were carried out for examination of the influence of *CLDN6* on cell invasion and migration. As observed in Figure 2A,2B, the downregulation of *CLDN6* significantly blocked the invasion and migration ability of the cells ( $P < 0.001$ ), and through wound healing assay, we can also see the same trend in Figure 2C,2D.

### Promotion of SMMC-7721 and MHCC-97H cell apoptosis by *CLDN6* silencing

The findings of the CCK-8 assay indicated inhibition of cell proliferation (Figure 3A,3B) after *CLDN6*-siRNA transfection at 24, 48, and 72 h ( $P < 0.01$ ,  $P < 0.001$ ). Flow cytometry was employed for analyzing tumor cell apoptosis (Figure 3C,3D). After *CLDN6* silencing, tumor cell apoptosis appeared remarkably greater in comparison to control cells ( $P < 0.001$ ). The results of WB (Figure 4A,4B) showed the same trend. These findings were indicative of the inhibitory effects of *CLDN6* knockdown on the proliferation of these cells, as well as its ability to promote cell apoptosis.

### Induction of apoptosis by *CLDN6* silencing via downregulation of JAK2/STAT3 signaling pathway activation

In oncogenesis, JAK2/STAT3 signaling is a vital regulator of tumor progression. To evaluate the influence of *CLDN6* knockdown on this pathway, the levels of JAK2/STAT3 pathway-related proteins were analyzed through Western blotting. As shown in picture 3, *CLDN6* silencing decreased the expression of p-JAK2, p-STAT3, p-JAK2/JAK2, p-STAT3/STAT3, *CLDN6*, and Bcl-2. However, Bax and cleaved caspase-3 expression levels were increased, while no remarkable differences were observed in JAK2 and STAT3 expression levels (Figure 4). These results clearly showed that *CLDN6* silencing induced apoptosis by downregulating



**Figure 1** Transfection of SMMC-7721 and MHCC-97H cells with *CLDN6*-siRNA or NC-siRNA for 48 h. (A,B) Detection of *CLDN6* expression by qRT-PCR, \*\*\*,  $P < 0.001$ . (C,D) Observation of fluorescence images under a laser scanning confocal microscope after fluorescent secondary antibody staining. siRNA, short interfering RNA; qRT-PCR, quantitative real-time polymerase chain reaction.


the activation of this pathway.

#### **Promotion of HCC cell invasion and migration and inhibition of apoptosis by *CLDN6* overexpression**


SMMC-7721 and MHCC-97H cells were transfected with pcDNA-NC or pcDNA-*CLDN6* sequence for 48 h. Western blotting showed increased expression of *CLDN6* (Figure 5A,5B), and immunofluorescence (Figure 1C,1D) analysis demonstrated overexpression, elevated Bcl-2 levels, and lowered Bax and cleaved caspase-3 levels. *CLDN6* overexpression resulted in the inhibition of HCC cell apoptosis (Figure 5A,5B). The ability of the aforementioned cells to invade and migrate was significantly increased following *CLDN6* overexpression. However, cell invasion and migration decreased significantly when a pathway inhibitor (AG490) was used (Figure 5C,5D). These results indicated that *CLDN6* regulates cell invasion and migration via JAK2/STAT3 pathway in these cells.

#### **Discussion**

TJs are essential for modulating cell polarity, adhesion, and permeability. They are present in the junctional complex connecting epithelial and endothelial cells (7), also, tight junctions must also be selectively permeable to ions, water, and macromolecules (8). Tumors and inflammatory tissues are characterized by decreased TJ integrity and increased cellular bypass permeability (9). The junction adhesion molecules, occludin, and CLDN are the three fundamental membrane proteins that make up TJs. The CLDN protein family is a vital regulator of TJ functioning (10). The CLDN family functions as an important modulator of tumorigenesis and metastasis, the altered expression of *CLDN6* is linked to the development of various cancers whose malignant phenotypes include proliferation and apoptosis, migration and invasion and drug resistance (11). *CLDN6* varies among tumor cells of various types. The expression of *CLDN6* in gastric cancer (12), non-small cell



**Figure 2** Inhibition of SMMC-7721 and MHCC-97H cell invasion and migration by *CLDN6* downregulation. (A,B) The cells crossed through the pores of Transwell chamber were stained by crystal violet. (C,D) Detection of cell invasion via wound-healing assay. Each bar represents the mean  $\pm$  SEM of three independent experiments (\*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; one-way ANOVA). siRNA, short interfering RNA; ANOVA, analysis of variance; SEM, standard error of the mean.




**Figure 3** Promotion of SMMC-7721 and MHCC-97H cell apoptosis by *CLDN6* silencing. (A,B) Inhibition of cell proliferation depicted by CCK-8 assay. (C,D) Analysis of apoptosis by flow cytometry 24 h after *CLDN6* silencing (\*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ). siRNA, short interfering RNA; CCK-8, Cell Counting Kit-8.

lung cancer (NSCLC) (13), ovarian cancer (14), endometrial cancer (15), and esophageal squamous cell carcinoma (16) are greater than the expression observed in normal tissues. However, its expression is down-regulated in cervical cancer (17) and is undetectable in breast cancer (18). The abnormality of *CLDN6* expression in some tumors renders *CLDN6* a possible targeting molecule for treating these tumors (19), such as breast cancer (20) and NSCLC (21). The primary objective of this research was the investigation of the *CLDN6* mechanism in HCC.

The most prevalent primary liver cancer is HCC, which is also the second-leading contributor to cancer-caused deaths globally (22), accounting for 75% to 85% of cases (23). HCC is the fastest increasing cause of cancer-related death and one of the leading causes of death in patients with compensated cirrhosis (24).


For early HCC, surgical resection and liver transplantation

are the major treatment strategies. However, large or multifocal tumors with co-existing liver lesions are sometimes unresectable. Although liver transplantation and surgical resection are the mainstays of HCC treatment, numerous patients are inoperable in advanced stages. In stark contrast to other cancers, HCC is considered resistant to systemic chemotherapy (25). Sorafenib is the first systematic treatment to increase the survival rates of patients with advanced liver cancer (26). Although sorafenib has been proven effective and safe for HCC treatment, its potential role as an adjuvant for HCC is still controversial (27). According to the results of recent clinical trials, a single drug may not be sufficient to treat liver cancer (28). Therefore, combined therapy is the main strategy for treating advanced liver cancer systemically. In addition, it is important to find new therapeutic targets. With the continuous development of new treatment strategies, HCC



**Figure 4** Induction of apoptosis via downregulation of JAK2/STAT3 signaling pathway activation by *CLDN6* silencing. Transfection of SMMC-7721 and MHCC-97H cells with *CLDN6*-siRNA or NC-siRNA sequence. (A,B) Attenuation in p-JAK2, p-STAT3, p-JAK2/JAK2, p-STAT3/STAT3, *CLDN6* and Bcl-2 expression and enhancement of Bax expression and cleaved caspase-3 levels via *CLDN6* silencing (\*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; one-way ANOVA). siRNA, short interfering RNA; ANOVA, analysis of variance.





**Figure 5** Reduction in the impact of *CLDN6* overexpression on cell invasion and migration via inhibition of the JAK2/STAT3 signaling pathway. Transfection of MMC-7721 and MHCC-97H cells with pcDNA-NC or pcDNA-*CLDN6* sequence. (A,B) Enhancement of Bcl-2 expression and attenuation in Bax expression and cleaved caspase-3 levels via *CLDN6* overexpression. (C,D) *CLDN6* overexpression. Assessment of cell invasion and migration by Transwell assay, which was stained by crystal violet. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .

outcomes are expected to be greatly improved in the future.

JAK/STAT signaling pathway is considered among the most important signal-cascading pathways in many cellular processes and is initiated by growth factors, cytokines, hormones, and other ligands. The JAK/STAT signal modulates several physiological mechanisms, including immunomodulation, cell proliferation, cell survival, apoptosis of myeloid and non-myeloid cells, and hematopoiesis (29). JAK/STAT is an evolutionarily conserved signal transduction pathway in all eukaryotes and the main signal transduction pathway for mammalian cytokines and growth factors, converting extracellular signals into transcriptional information to regulate physiological processes (30). Abnormal activation of intracellular signaling pathways causes cells with genetic and metabolic changes to show malignant phenotypes (31). Numerous changes are observed in signaling pathways regulating cell growth, division, death, fate, movement, tumor microenvironment, angiogenesis, and inflammation (32). In addition to the regulation of physiological processes, alterations in this signaling pathway also function in some pathophysiological diseases, including malignant tumors. Research has shown the activation of this pathway in multiple cancers, including HCC. Multiple effects of this pathway on cells and its association with other signaling pathways are key markers for the onset and development of cancer. Therefore, targeted activation of this pathway is a reasonable strategy for treating tumors (33). This pathway regulates various biological processes. However, it is particularly important for cell division, cell death (34), and tumor formation (35). Many mechanisms regulate JAK2/STAT3 signal transduction, in which tyrosine kinases are crucial. The synergistic effect of these mechanisms ensures optimal cell function during normal physiology and prevents inappropriate cell activities associated with the onset of diseases, such as tumors (36). STAT3 promotes cell invasion by adjusting matrix metalloproteinases (MMP) expression, such as MMP-2 and MMP-9 MMP (37). In addition, STAT3 also causes enhancement of HCC cell invasion via upregulation of the expression of Slug, Twist, and other epithelial-mesenchymal transition proteins (38). Other pathways involved in tumor metastasis, such as the PI3K/Akt2 signaling pathway, are also regulated by STAT3, which can synergistically increase tumor invasiveness (39). It is considered a strong candidate gene for the promotion of tumorigenesis in many human cancers, including the HCC (40). As a transcription factor, STAT3 stimulation promotes the expression of multiple genes, producing plenty

of cancer markers. This finding highlights the carcinogenic role of STAT3 in the HCC (33). STAT3 is related to the adaptation of cancer cell metabolic processes to produce large amounts of energy biomolecules that promote cell survival (41). Therefore, JAK2/STAT3 signaling pathway is a vital regulator of liver cancer onset and advancement and may become a potential target for future clinical treatment.

This research observed that *CLDN6* knockdown could reduce the invasive and migratory capacities of cells and inhibit JAK2/STAT3 signaling pathway activation. A particular effect was observed on p-JAK2 and p-STAT3 proteins, which was characterized by reduced expression levels of these proteins and increased apoptosis. The expression of anti-apoptotic protein Bcl-2 was decreased, and cleaved caspase-3 and Bax expression were contrasting. Conversely, *CLDN6* overexpression can prevent apoptosis while promoting cell migration and invasion. The increase in Bcl2 expression level and the lowered expression levels of Bax and cleaved caspase-3 backed this hypothesis. Collectively, these findings are indicative of the involvement of *CLDN6* in HCC progression by regulating the JAK2/STAT3 signaling pathway.

## Conclusions

In conclusion, *CLDN6* is a promising treatment target for HCC, but subsequent research is required to completely understand its underlying mechanisms and associated adverse effects to enhance therapeutic efficiency and potential individualized patient therapy. The JAK2/STAT3 signaling pathway's diverse cellular effects, as well as how it interacts with other signaling pathways, are crucial for the onset and progression of cancers. Therefore, targeted activation JAK2/STAT3 pathway is a reasonable strategy to treat tumors with the modulation of this abnormal signaling pathway. The findings of this study demonstrate that the downregulation of *CLDN6* is sufficient for the reduction of the invading and migrating ability of HCC cells and ultimately resulting in the death of HCC cells by inactivating the JAK2/STAT3 signaling pathway. This suggests that *CLDN6* may be a biomarker of HCC with potential value as a therapeutic target.

## Acknowledgments

*Funding:* This study was funded by Science Research Project of Anhui Educational Committee (No. 2022AH040216), Bengbu Medical College 512 Talent Cultivation Program

(No. by51201216), Key Natural Science Project of Bengbu Medical College (No. 2020byzd170), and the Scientific Research Innovation Program of postgraduates in Bengbu Medical College (No. Byycx20023).

## Footnote

*Reporting Checklist:* The authors have completed the MDAR reporting checklist. Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-23-19/rc>

*Data Sharing Statement:* Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-23-19/dss>

*Peer Review File:* Available at <https://tcr.amegroups.com/article/view/10.21037/tcr-23-19/prf>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://tcr.amegroups.com/article/view/10.21037/tcr-23-19/coif>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65:87-108.
2. Mineta K, Yamamoto Y, Yamazaki Y, et al. Predicted expansion of the claudin multigene family. *FEBS Lett* 2011;585:606-12.
3. Osanai M, Takasawa A, Murata M, et al. Claudins in cancer: bench to bedside. *Pflugers Arch* 2017;469:55-67.
4. Zihni C, Mills C, Matter K, et al. Tight junctions: from simple barriers to multifunctional molecular gates. *Nat Rev Mol Cell Biol* 2016;17:564-80.
5. Krause G, Winkler L, Mueller SL, et al. Structure and function of claudins. *Biochim Biophys Acta* 2008;1778:631-45.
6. Kwon MJ, Kim SH, Jeong HM, et al. Claudin-4 overexpression is associated with epigenetic derepression in gastric carcinoma. *Lab Invest* 2011;91:1652-67.
7. Li J, Ananthapanyasut W, Yu AS. Claudins in renal physiology and disease. *Pediatr Nephrol* 2011;26:2133-42.
8. Hu CA, Hou Y, Yi D, et al. Autophagy and tight junction proteins in the intestine and intestinal diseases. *Anim Nutr* 2015;1:123-7.
9. English DP, Santin AD. Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy. *Int J Mol Sci* 2013;14:10412-37.
10. Ushiku T, Shinozaki-Ushiku A, Maeda D, et al. Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas. *Histopathology* 2012;61:1043-56.
11. Anderson WJ, Zhou Q, Alcalde V, et al. Genetic targeting of the endoderm with claudin-6CreER. *Dev Dyn* 2008;237:504-12.
12. Zavala-Zendejas VE, Torres-Martinez AC, Salas-Morales B, et al. Claudin-6, 7, or 9 overexpression in the human gastric adenocarcinoma cell line AGS increases its invasiveness, migration, and proliferation rate. *Cancer Invest* 2011;29:1-11.
13. Micke P, Mattsson JS, Edlund K, et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. *Int J Cancer* 2014;135:2206-14.
14. Wang L, Jin X, Lin D, et al. Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma. *Diagn Pathol* 2013;8:190.
15. Cao X, He GZ. Knockdown of CLDN6 inhibits cell proliferation and migration via PI3K/AKT/mTOR signaling pathway in endometrial carcinoma cell line HEC-1-B. *Onco Targets Ther* 2018;11:6351-60.
16. Tsunoda S, Smith E, De Young NJ, et al. Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. *Oncol Rep* 2009;21:1067-73.
17. Zhang X, Ruan Y, Li Y, et al. Expression of apoptosis signal-regulating kinase 1 is associated with tight junction protein claudin-6 in cervical carcinoma. *Int J Clin Exp Pathol* 2015;8:5535-41.
18. Jia H, Chai X, Li S, et al. Identification of claudin-2, -6, -11 and -14 as prognostic markers in human breast

- carcinoma. *Int J Clin Exp Pathol* 2019;12:2195-204.
19. Du H, Yang X, Fan J, et al. Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review). *Mol Med Rep* 2021;24:677.
  20. Yafang L, Qiong W, Yue R, et al. Role of Estrogen Receptor-alpha in the Regulation of Claudin-6 Expression in Breast Cancer Cells. *J Breast Cancer* 2011;14:20-7.
  21. Wang Q, Zhang Y, Zhang T, et al. Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer. *Onco Targets Ther* 2015;8:1971-7.
  22. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394-424.
  23. Zhang H, Zhang W, Jiang L, et al. Recent advances in systemic therapy for hepatocellular carcinoma. *Biomark Res* 2022;10:3.
  24. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004;127:S35-50.
  25. Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al. Hepatocellular carcinoma: From diagnosis to treatment. *Surg Oncol* 2016;25:74-85.
  26. Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. *Nat Rev Clin Oncol* 2022;19:151-72.
  27. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2015;16:1344-54.
  28. Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: Looking outside the box. *J Hepatol* 2020;72:342-52.
  29. Rah B, Rather RA, Bhat GR, et al. JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies. *Front Pharmacol* 2022;13:821344.
  30. O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. *Annu Rev Med* 2015;66:311-28.
  31. Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. *Science* 2017;357:eaal2380.
  32. Jing X, Yang F, Shao C, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. *Mol Cancer* 2019;18:157.
  33. Hin Tang JJ, Hao Thng DK, Lim JJ, et al. JAK/STAT signaling in hepatocellular carcinoma. *Hepat Oncol* 2020;7:HEP18.
  34. Park SY, Lee CJ, Choi JH, et al. The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance. *J Exp Clin Cancer Res* 2019;38:399.
  35. Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. *Growth Factors* 2012;30:88-106.
  36. Mengie Ayele T, Tilahun Muche Z, Behaile Teklemariam A, et al. Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review. *J Inflamm Res* 2022;15:1349-64.
  37. Huang L, Jian Z, Gao Y, et al. RPN2 promotes metastasis of hepatocellular carcinoma cell and inhibits autophagy via STAT3 and NF- $\kappa$ B pathways. *Aging (Albany NY)* 2019;11:6674-90.
  38. Kang FB, Wang L, Jia HC, et al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. *Cancer Cell Int* 2015;15:45.
  39. Xie Y, Li J, Zhang C. STAT3 promotes the proliferation and migration of hepatocellular carcinoma cells by regulating AKT2. *Oncol Lett* 2018;15:3333-8.
  40. Khan AQ, Ahmed EI, Elareer NR, et al. Role of miRNA-Regulated Cancer Stem Cells in the Pathogenesis of Human Malignancies. *Cells* 2019;8:840.
  41. Huynh J, Chand A, Gough D, et al. Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. *Nat Rev Cancer* 2019;19:82-96.

**Cite this article as:** He Z, Fan F, Xu Z, Zhang M, Zhao R, Ke X, Wang Q, Yan S, Zheng H. Downregulation of *CLDN6* inhibits cell migration and invasion and promotes apoptosis by regulation of the JAK2/STAT3 signaling pathway in hepatocellular carcinoma. *Transl Cancer Res* 2023;12(7):1753-1764. doi: 10.21037/tcr-23-19